#ESMO22 Highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. RCC: COSMIC-313 Published 2022-09-12 Download video MP4 360p Recommendations 08:07 TKI/IO Comparison: Lenvatinib/Pembrolizumab vs Cabozantinib/Nivolumab vs Axitinib/Pembrolizumab 04:57 Precision Medicine in Carcinoma of Unknown Primary with Alwin Krämer 02:35 Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma 38:47 Renal cell carcinoma 09:15 Caffeine, Health, and the Human Body 51:09 Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: ASCO GU 2023 22:49 Highlights of the 2023 San Antonio Breast Cancer Symposium With Jason Mouabbi, MD 01:49 COSMIC-313: cabozantinib with nivolumab and ipilimumab in untreated aRCC 1:06:11 Robert Lustig,MD-Everything You Knew About Obesity is Wrong! Personal Responsibility / Public Health 16:43 Lung Cancer Staging with the IASLC Lymph Node Map 01:04 Dr. Wei on the Use of Cabozantinib in Advanced Kidney Cancer 01:39 What is GP Connect? — NHS Digital 55:12 Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCC 57:38 ESMO Patient Guides: Let's talk about oesophageal and stomach cancers 01:05 Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCC 44:24 Basics of EP Testing and Ablation by Adam Zivin, M.D. 22:11 My Acute Transverse Myelitis Story 14:12 Kidney Biopsy #nephroticsyndrome #minimalchangedisease #kidneybiopsy 01:25 Managing side effects of cabozantinib treatment for metastatic renal cell carcinoma Similar videos 04:22 Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk signif... 04:23 ESMO22: cabozantinib in combination with nivo & ipi in previously untreated aRCC of IMDC interme... 06:50 ESMO 2022: Renal roundup 03:16 #ESMO22 Highlights on TILs versus ipilimumab in patients with advanced melanoma: The phase 3 study 02:46 #ESMO22 Highlights on neoadjuvant ICI in locally advanced dMMR colon cancer: The NICHE-2 study 02:01 ESMO22: Toni Choueiri, MD | Dana-Farber Cancer Institute 03:56 Cabozantinib as Immune Modulatory Therapy for Advanced RCC 01:26 Neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccRCC 08:48 Nivo + ipi in RCC: OMNIVORE 25:09 Kidney Cancer Highlights from ESMO 2022 17:18 Cabozantinib Safety with Anticoagulants in Patients with Renal Cell Carcinoma 07:08 Final analysis of the ATLANTIS cabozantinib comparison 04:06 COSMIC-313 Trial Results and Implications for Triplet RCC Therapy 03:43 Telaglenastat Plus Cabozantinib for Advanced Renal Cell Carcinoma 03:35 #ESMO22 Highlights on actionable inflammatory axis for air pollution induced NSCLC 02:21 #ESMO22 Highlights on ADT duration with post-operative radiotherapy in prostate cancer: RADICALS-HD More results